Thyrotropin Releasing Hormone (TRH), often called Protirelin, is a small peptide hormone made of 3 amino acids and synthesized in the hypothalamus. The hormone is thought to function via binding to the thyrotropin-releasing hormone receptors TRH-1 and TRH-2. It was developed by researchers with the intention to stimulate the release of both thyroid-stimulating hormone (TSH) and prolactin from the anterior pituitary. TSH, in turn, acts directly on the thyroid gland to promote the synthesis and release of thyroid hormones, primarily triiodothyronine (T3) and thyroxine (T4). TRH has been employed in the study of anterior pituitary gland function in models of thyroid disorders. TRH may exhibit potential roles in TREK-1 channel, in the regulation of cellular aging, arousal, feeding behaviors, autonomic regulation, and mitigating free radical damage.

Specifications

Molecular Formula: C₁₄H₂₂N₄O₉

Molecular Weight: 390.34 g/mol

Sequence: Ala-Glu-Asp-Gly

Other Known Titles: Epitalon, Epithalone, Epithalamin

Specifications

Molecular Formula: C₄₀₀H₆₂₅N₁₁₁O₁₁₅S₉

Molecular Weight: 9117.5 g/mol

Sequence: MFPAMPLSSL FVNGPRTLCG AELVDALQFV CGDRGFYFNK PTGYGSSSRR APQTGIVDEC CFRSCDLRRL EMYCAPLKPA KSA

Thymalin, sometimes referred to as Thymalin Alpha-1, is the synthetic variant of the endogenous Thymulin, which was first isolated from the thymus in 1977. The endogenously produced Thymalin has been researched for its potential in a wide landscape of research areas, with its influence speculated to extend to regulatory action on inflammation, mitigation of pain perception, neuroprotective action, and immune function support. Early studies have suggested that Thymalin and other thymus and pineal gland secretions may also support cell longevity.

Thymosin Alpha-1, also known as TA1 or Tα1, is a naturally occurring peptide fragment that was discovered in 1972 and researched for its potential action within the context of studies relating to cystic fibrosis, infection (e.g., tuberculosis, cytomegalovirus), respiratory disorders, chronic hepatitis, and cancer. It is also referred to as Thymalfasin when synthetically developed. Originally, research on Thymosin Alpha-1 centered around its potential role in immune modulation. It is hypothesized that it might increase levels of Major Histocompatibility Complex (MHC) class I molecules and boost cytokine production, key components of the immune system that may enhance immune responses.^[1][2] There is also a possibility that it might improve the activity of natural killer cells, which target virus-infected cells and tumors. Furthermore, it might enhance the expression of specific markers on T cells that are considered critical for their identification and function in the immune system, indicating a significant role in immune regulation. Thymosin Alpha-1 is also thought to possibly increase the presence of high-affinity interleukin-2 receptors on cell surfaces, potentially leading to the vigorous activation and proliferation of T lymphocytes, elements of immune response. There is speculation that it may affect both T-helper and cytotoxic T-cell populations, deemed essential for eliminating infected cells. Additionally, it might prompt the differentiation of thymocytes—precursor cells in the thymus—and peripheral blood lymphocytes into mature immune cells, increase natural killer cell numbers, and promote cytokine-driven inflammatory responses. Research also explores its potential role in enhancing macrophage efficiency—cells that engulf and digest pathogens—and in regulating the activity of alpha thrombin, a protein involved in blood clotting, highlighting its broad potential on immune function.

Humanin is an endogenously occurring unique peptide encoded by mitochondrial DNA. The peptide may exist in two different forms found in the cell: a 21 amino acid sequence found inside the cell’s mitochondria, and a 24 amino acid sequence found outside the cell’s cytosol. Both forms appear to act as cytoprotective proteins and may protect cells from the process of apoptosis (programmed cell death) by interfering with the operation of the Bcl2-related X protein (Bax).^[1]

Bax is considered a pro-apoptotic protein that promotes apoptosis by disrupting the mitochondrial outer membrane. It is believed to facilitate the release of cytochrome c from mitochondria into the cytosol, which then triggers a cascade of events leading to cell death. By interfering with Bax’s function, Humanin may help support the initiation of this apoptotic pathway. Researchers posit that Humanin may “[support] the translocation of Bax from the cytosol to mitochondria. Conversely, reducing Humanin expression by small interfering RNAs sensitizes cells to Bax and increases Bax translocation to membranes.”

Apart from research into its possible interaction with Bax, Humanin studies suggest the peptide may also bind with other intracellular molecules, such as actinin-4 and phosphoprotein 8, which are both involved in cellular apoptosis. Binding with these proteins is also thought to contribute to Humanin’s cytoprotective potential.^[2] Thus, studies suggest that Humanin may be important for protecting a variety of cells, most notably neurons. In addition, studies also suggest it may have a protective potential for cells in heart tissue, muscle cells, the retina of the eye, and the lining of blood vessels.

PNC-27 is a synthetic peptide initially developed for its proposed inhibitive action on cancer cell proliferation. It is a member of the PNC family of probe proteins and is designed to attach to malformed cancer cells and induce cell necrosis, but bypass normal functioning cells. The PNC-27 peptide contains the HDM2 binding domain and transmembrane domain corresponding to residue 1226 on p53. Researchers suggest that it exhibits potential to bind to and kill cancer cells through membrane lysis or cell membrane destruction. Research studies have suggested that the PNC-27 peptide may be selective in targeting specific cancer cell types, prompting further research within the context of pancreatic cancer, breast cancer, leukemia, melanoma, and other cancer strains.^[1]

The PNC protein was first developed in 2000. The PNC-27 peptide appears to be a non-toxic compound, attaching to and puncturing the membranes of individual cancer cells. As a result, rapid implosion may occur, leading to immediate cell death due to differences in osmotic pressure inside and outside the tumor cells. PNC-27 appears to have this potential through an affinity for binding to a protein called HDM2. Cancer cells typically display HDM2 in their cell membranes.^[2] According to the researchers “PNC-27 targets HDM-2 in the membranes of cancer cells, allowing it to induce membranolysis of these cells selectively.” Immediately after exposure to the PNC-27 peptide, studies have observed that the peptide appears to move to HDM2. Binding to them creates pores or holes in the cell membrane, causing “membrane lysis” or death of the cell membrane. This process, in turn, may lead to the destruction of cancer cells. Research is ongoing.